Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific ...(sparities in outcomes and high case fata...),Health

Date:4/1/2008

sparities in outcomes and high case fatality rates. Addressing this problem will require an honest broker to access areas of duplicative research, which is why EDICT recommends that the Institute of Medicine conduct a new study that will recommend strategies for eliminating duplication and promoting coordination. Based on this assessment, Congress will be able to ensure that federal research funding complements private sector funding and gives priority to diseases with the greatest disparities and the highest case fatality rates.

7. Enhance public education about clinical trials. Lack of awareness about clinical trials, fear or mistrust of medical research, and the complexity of consent forms and other clinical trials materials are major barriers to patient accrual. Accordingly, the report calls for the widespread development and implementation of culturally appropriate recruitment and retention plans with an additional focus on community education provided in appropriate languages for non-English and limited-English speaking populations.

8. Implement participant navigation as a critical element of the clinical trials process. Modeled after the "navigator" program created at Harlem Hospital, patient navigation is a new tool that helps patients keep their appointments and solves their non-medical problems. Because of its potential to retain patients in medical research studies, an analogous process termed "participant navigation" should become the accepted standard of practice for institutions conducting clinical trials.

9. Assure insurance coverage of the costs associated with clinical trials. The costs associated with participating in a clinical trial are a concern to all patients and have remained a major barrier to patient accrual. Addressing this problem will require actions by both policy makers and the business community to identify and close any existing gaps and to produce and disseminate easy-to-understand information about what the ins
'/>"/>

SOURCE Eliminating Disparities in Clinical Trials Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
2. Cancer Cure Coalition Proposes Major Changes at the FDA
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
5. Penn Research Shows Transcranial Magnetic Stimulation Effective in Treating Major Depression
6. Two Major Studies Show: Human Pluripotent Stem Cells without Cloning or Destroying Embryo
7. Fabre Kramer Pharmaceuticals Receives Decision From FDA on Gepirone ER for Major Depressive Disorder
8. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
9. Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting
10. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
11. EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimers, Schizophrenia and Huntingtons Diseases